This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Clinical features

Authoring team

clinical features

Ingestion of oocysts, which contain the infective stage of parasites life cycle, results in the disease

  • symptoms are usually present two to ten days (average seven days) after becoming infected with the parasite

  • patients presents with gastroenteritis like syndrome
    • small bowel is affected mainly with malabsorption and some elements of inflammation
    • profuse, usually non-bloody, and watery diarrhoea is usually associated with
      • abdominal cramps (in 96% of patients who present for consultation)
      • vomiting (65%)
      • mild fever (59%)
      • loss of appetite
      • weight loss
    • mean duration of symptoms is around 12.7 days, but in some patients may persist up to a month
    • persistent infection may result in relapse of symptoms in over a third of cases

  • patients who are immunocompromised commonly experience chronic or intractable disease
    • entire gastrointestinal tract can be affected, including the pancreatic duct and gall bladder (1).

Several long term effects of Cryptosporidium infection have been reported:

  • in C. hominis - joint pain, eye pain, headaches, and fatigue during the two months after infection
  • seronegative reactive arthritis - both in adults and in children (including one report of Reiter's syndrome)
  • relapse of inflammatory bowel disease (1).

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.